292 related articles for article (PubMed ID: 24697749)
1. A hybrid design to optimize preparation of lopinavir loaded solid lipid nanoparticles and comparative pharmacokinetic evaluation with marketed lopinavir/ritonavir coformulation.
Ravi PR; Vats R; Dalal V; Murthy AN
J Pharm Pharmacol; 2014 Jul; 66(7):912-26. PubMed ID: 24697749
[TBL] [Abstract][Full Text] [Related]
2. Design, optimization and evaluation of poly-ε-caprolactone (PCL) based polymeric nanoparticles for oral delivery of lopinavir.
Ravi PR; Vats R; Dalal V; Gadekar N; N A
Drug Dev Ind Pharm; 2015 Jan; 41(1):131-40. PubMed ID: 24180260
[TBL] [Abstract][Full Text] [Related]
3. Comparative pharmacokinetic evaluation of lopinavir and lopinavir-loaded solid lipid nanoparticles in hepatic impaired rat model.
Ravi PR; Vats R
J Pharm Pharmacol; 2017 Jul; 69(7):823-833. PubMed ID: 28317117
[TBL] [Abstract][Full Text] [Related]
4. Effect of grapefruit juice and ritonavir on pharmacokinetics of lopinavir in Wistar rats.
Ravi PR; Vats R; Thakur R; Srivani S; Aditya N
Phytother Res; 2012 Oct; 26(10):1490-5. PubMed ID: 22308076
[TBL] [Abstract][Full Text] [Related]
5. QbD based development of proliposome of lopinavir for improved oral bioavailability.
Patel GM; Shelat PK; Lalwani AN
Eur J Pharm Sci; 2017 Oct; 108():50-61. PubMed ID: 27586019
[TBL] [Abstract][Full Text] [Related]
6. Development and in vivo evaluation of child-friendly lopinavir/ritonavir pediatric granules utilizing novel in situ self-assembly nanoparticles.
Pham K; Li D; Guo S; Penzak S; Dong X
J Control Release; 2016 Mar; 226():88-97. PubMed ID: 26849919
[TBL] [Abstract][Full Text] [Related]
7. Modified pullulan nanoparticles for oral delivery of lopinavir: formulation and pharmacokinetic evaluation.
Ravi PR; Vats R; Balija J; Adapa SP; Aditya N
Carbohydr Polym; 2014 Sep; 110():320-8. PubMed ID: 24906762
[TBL] [Abstract][Full Text] [Related]
8. Statistical modeling, optimization and characterization of solid self-nanoemulsifying drug delivery system of lopinavir using design of experiment.
Patel G; Shelat P; Lalwani A
Drug Deliv; 2016 Oct; 23(8):3027-3042. PubMed ID: 26882014
[TBL] [Abstract][Full Text] [Related]
9. Development of solid lipid nanoparticles (SLNs) of lopinavir using hot self nano-emulsification (SNE) technique.
Negi JS; Chattopadhyay P; Sharma AK; Ram V
Eur J Pharm Sci; 2013 Jan; 48(1-2):231-9. PubMed ID: 23153618
[TBL] [Abstract][Full Text] [Related]
10. Formulation and in-vivo Evaluation of Novel Topical Gel of Lopinavir for Targeting HIV.
Ansari H; Singh P
Curr HIV Res; 2018; 16(4):270-279. PubMed ID: 30246641
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients.
López Aspiroz E; Santos Buelga D; Cabrera Figueroa S; López Galera RM; Ribera Pascuet E; Domínguez-Gil Hurlé A; García Sánchez MJ
Ther Drug Monit; 2011 Oct; 33(5):573-82. PubMed ID: 21912331
[TBL] [Abstract][Full Text] [Related]
12. Low dose lopinavir/ritonavir tablet achieves adequate pharmacokinetic parameters in HIV-infected Thai adolescents.
Klinklom A; Puthanakit T; Gorowara M; Phasomsap C; Kerr S; Sriheara C; Ananworanich J; Burger D; Ruxrungtham K; Pancharoen C
Antivir Ther; 2012; 17(2):283-9. PubMed ID: 22293065
[TBL] [Abstract][Full Text] [Related]
13. Curcumin-loaded solid lipid nanoparticles with Brij78 and TPGS improved in vivo oral bioavailability and in situ intestinal absorption of curcumin.
Ji H; Tang J; Li M; Ren J; Zheng N; Wu L
Drug Deliv; 2016; 23(2):459-70. PubMed ID: 24892628
[TBL] [Abstract][Full Text] [Related]
14. Integrated population pharmacokinetic/viral dynamic modelling of lopinavir/ritonavir in HIV-1 treatment-naïve patients.
Wang K; D'Argenio DZ; Acosta EP; Sheth AN; Delille C; Lennox JL; Kerstner-Wood C; Ofotokun I
Clin Pharmacokinet; 2014 Apr; 53(4):361-71. PubMed ID: 24311282
[TBL] [Abstract][Full Text] [Related]
15. Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men.
Umeh OC; Currier JS; Park JG; Cramer Y; Hermes AE; Fletcher CV
J Clin Pharmacol; 2011 Dec; 51(12):1665-73. PubMed ID: 21233301
[TBL] [Abstract][Full Text] [Related]
16. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
[TBL] [Abstract][Full Text] [Related]
17. Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates.
Freeling JP; Koehn J; Shu C; Sun J; Ho RJ
AIDS Res Hum Retroviruses; 2015 Jan; 31(1):107-14. PubMed ID: 25402233
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects.
Wire MB; McLean HB; Pendry C; Theodore D; Park JW; Peng B
Antimicrob Agents Chemother; 2012 Jun; 56(6):2846-51. PubMed ID: 22391553
[TBL] [Abstract][Full Text] [Related]
19. Multivariate Optimization of Rizatriptan Benzoate-Loaded Solid Lipid Nanoparticles for Brain Targeting and Migraine Management.
Girotra P; Singh SK
AAPS PharmSciTech; 2017 Feb; 18(2):517-528. PubMed ID: 27126007
[TBL] [Abstract][Full Text] [Related]
20. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction.
Lim ML; Min SS; Eron JJ; Bertz RJ; Robinson M; Gaedigk A; Kashuba AD
J Acquir Immune Defic Syndr; 2004 Aug; 36(5):1034-40. PubMed ID: 15247556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
